Core Insights - Haisheng Pharmaceutical reported a revenue of 101 million yuan in the first half of 2025, representing a year-on-year growth of 42.14% and a net profit of 30.33 million yuan, up 29.33% year-on-year [1] - The company is a key supplier in the veterinary and pharmaceutical raw materials sector, capitalizing on the recovery of the aquaculture industry and expanding its revenue sources through new product launches and successful fundraising projects [1][3] Industry Trends - The global aging population is projected to reach nearly 1.6 billion by 2050, with 16% of the population aged 65 and older, driving demand for chronic disease management and elderly care medications [2] - The Chinese elderly population is expected to reach 310 million by the end of 2024, accounting for 22% of the total population, further increasing the demand for pharmaceuticals [2] - The global veterinary drug market is expected to exceed 60 billion USD by 2025, with a compound annual growth rate (CAGR) of 7.5% from 2022 to 2025 [2] Company Performance - In the first half of 2025, Haisheng Pharmaceutical's raw materials and intermediates business generated revenues of 77.94 million yuan and 22.71 million yuan, respectively, with year-on-year growth rates of 58.14% and 5.46% [3] - The gross profit margins for raw materials and intermediates were 43.81% and 42.25%, indicating strong product competitiveness and market expansion effectiveness [3] R&D and Innovation - Haisheng Pharmaceutical maintains a high level of R&D investment, with expenditures of 5.17% of revenue in the first half of 2025, reflecting a year-on-year increase of 28.68% [4] - The company has developed core patented technologies that effectively reduce production costs and ensure product quality consistency, supporting profitability and market competitiveness [4] Market Strategy - The company achieved domestic revenue of 78.44 million yuan and international revenue of 22.41 million yuan in the first half of 2025, with gross margins of 39.70% and 56.34%, respectively [5][6] - Haisheng Pharmaceutical is expanding its global market presence while optimizing internal operations and technical capabilities, which is expected to drive revenue growth [5][6] Client Relationships - The company has established partnerships with notable domestic and international clients, ensuring stable sales growth and continuous operational optimization [7] - Haisheng Pharmaceutical is well-positioned to capture opportunities arising from the recovery of the aquaculture industry and the expansion of its product offerings [7]

Core Insights - The online consultation market in China is experiencing explosive growth, driven by the fast-paced modern lifestyle and increasing health awareness among the population. The market size is projected to reach 69.54 billion yuan in 2024, reflecting a year-on-year increase of 23.4% [1][11]. Online Consultation Industry Overview - Online consultation refers to a medical service model that allows patients to communicate with doctors remotely via internet platforms, breaking geographical barriers and utilizing various communication methods such as video, text, and voice [2]. - The industry has evolved through three main stages: the nascent phase (2000-2014), the initiation phase (2015-2016), and the rapid development phase (2017-present) [4][5]. Industry Development and Trends - The COVID-19 pandemic has accelerated the acceptance of online consultations, leading to increased government support and policy initiatives aimed at promoting remote medical services [6]. - The number of healthcare institutions in China is projected to grow from 1,007,600 in 2019 to 1,093,600 in 2024, driven by rising healthcare demands due to an aging population and chronic disease prevalence [8][9]. Competitive Landscape - The online consultation industry features a diverse competitive landscape, including comprehensive medical platforms, specialized medical platforms, and pharmaceutical e-commerce platforms. Major players include Ping An Good Doctor, JD Health, and Alibaba Health [11][12]. Future Development Directions - The integration of advanced technologies such as artificial intelligence and big data is expected to enhance the efficiency and accuracy of online consultation services [13]. - Establishing a robust regulatory framework for medical service quality is crucial for the sustainable development of the online consultation industry, addressing challenges such as verifying medical qualifications and ensuring accurate diagnoses [14]. - Data security and privacy protection are paramount, as the industry handles sensitive patient information. Strengthening data management practices and employing advanced encryption technologies are essential for safeguarding patient data [15].

Core Insights - Haisheng Pharmaceutical (stock code: 870656) reported a strong performance in the first half of 2025, achieving revenue of 101 million yuan, a year-on-year increase of 42.14%, and a net profit of 30.33 million yuan, up 29.33% [2][3] - The company focuses on core businesses including veterinary drug raw materials, pharmaceutical raw materials, and intermediates, which contributed to double-digit growth in both revenue and profit [2][3] Business Performance - The raw material drug segment remains the main growth driver, generating revenue of 77.94 million yuan, a 58.14% increase, with a gross margin of 43.81% [3] - The intermediates segment achieved revenue of 22.71 million yuan, reflecting a 5.46% growth [3] - Domestic market revenue reached 78.44 million yuan, a 64.35% increase, benefiting from rising demand in the downstream aquaculture industry, with a gross margin of 39.70% [3] - The overseas market faced challenges due to exchange rate fluctuations and international competition, resulting in revenue of 22.41 million yuan, a decline of 3.51%, but maintaining a high gross margin of 56.34% [3] Research and Development - R&D expenses for the first half of 2025 amounted to 5.21 million yuan, a 28.68% increase, focusing on process optimization and new product development for raw materials and intermediates [3] - Ongoing capacity expansion projects, including the 200-ton Celecoxib upgrade and 150-ton Tranexamic Acid production, are progressing well, with some projects entering equipment debugging stages [3] Compliance and Environmental Responsibility - The company adheres strictly to safety and environmental regulations, with no major incidents reported during the reporting period [4] - A comprehensive waste treatment system is in place, ensuring compliance with national and local environmental standards [4] Future Outlook - Haisheng Pharmaceutical plans to continue focusing on core businesses, accelerate project construction, and expand both domestic and emerging overseas markets to achieve steady annual growth [4] - The company aims to leverage its technological accumulation, capacity reserves, and compliance advantages to strengthen its market position amid ongoing industry expansion and recovering downstream demand [4]

Group 1: Company Performance - During the first half of 2025, the company achieved operating revenue of 101 million yuan, a year-on-year increase of 42.14% [1] - The total profit reached 35 million yuan, reflecting a year-on-year growth of 29.72% [1] - The net profit attributable to shareholders was 30 million yuan, with a year-on-year increase of 29.33% [1] Group 2: Competitive Advantages - The company is a significant supplier of sulfonamide drugs globally, with a long product chain and self-production of key intermediates, which mitigates supply shortages [1] - The company has a strong position in the veterinary raw materials market, with its core product SPDZ showing high sales revenue [2] - The company employs a flexible production model based on sales, enhancing market adaptability and resilience to cyclical fluctuations [2] Group 3: Market Trends - The global veterinary drug market is projected to grow from approximately 44.59 billion USD in 2022 to about 83.76 billion USD by 2030, with a compound annual growth rate (CAGR) of 8.2% [2] - The domestic veterinary drug market is expected to expand from 68.62 billion yuan in 2021 to 139.57 billion yuan by 2027, with a CAGR of 12.56% [3] - The company is focusing on expanding its product offerings in both sulfonamide and non-sulfonamide raw materials, as well as pet medications [3] Group 4: Shareholder Returns - The company implemented a high cash dividend and stock transfer plan, distributing 20 million yuan in cash dividends and increasing its total share capital to 100 million shares [4] - This initiative reflects the company's strong profitability and commitment to shareholder returns [4]

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a focus on high-growth sectors and mentions the potential for structural differentiation in the market [4][34]. Core Insights - The market experienced a decline, with the North Exchange A-share trading volume reaching 36.819 billion yuan, down by 3.87 billion yuan from the previous trading day, and the North Exchange 50 Index closing at 1589.40, down 1.60% [2][8]. - There is a notable divergence in stock performance, with certain sectors like information technology and healthcare showing resilience, while others, particularly in the automotive parts sector, faced significant adjustments [4]. - The report highlights the importance of government support for specialized and innovative enterprises, indicating that the recent deep adjustment in the North Exchange specialized and innovative index may provide a window for medium to long-term investment [4][20]. Summary by Sections Market Review - On August 21, the North Exchange A-share trading volume was 36.819 billion yuan, a decrease of 3.87 billion yuan from the previous day, with the North Exchange 50 Index closing at 1589.40, down 1.60% [2][8]. - Among 272 companies listed on the North Exchange, 71 saw an increase, 6 remained flat, and 195 experienced a decline [16]. Key Company Announcements - Haisheng Pharmaceutical reported a revenue of 130 million yuan for the first half of 2025, a year-on-year increase of 22.04%, with a net profit of 31 million yuan, up 35.87% [22]. - Kangle Guardian reported a revenue of 102 million yuan for the first half of 2025, a year-on-year increase of 4.66%, with a net profit of 10 million yuan, up 1.47% [23]. Important News - The government plans to introduce a 500 billion yuan "quasi-fiscal" tool to support emerging industries and infrastructure, focusing on areas such as the digital economy, artificial intelligence, and green low-carbon initiatives [20]. - DeepSeek released a new version optimized for next-generation domestic chips, enhancing efficiency and agent capabilities [21].

Core Insights - Haisheng Pharmaceutical (870656.BJ) released its semi-annual report for 2025 on August 21, 2025, indicating a total of 8 institutional investors holding shares in the company [1] - The total shareholding by institutional investors reached 4.27% of Haisheng Pharmaceutical's total equity, amounting to 4.2697 million shares [1] - Compared to the previous quarter, the proportion of shares held by institutional investors increased by 0.45 percentage points [1] Institutional Holdings - Eight institutional investors disclosed their holdings in Haisheng Pharmaceutical A-shares [1] - The institutional investors include Qizhou Youming Enterprise Management Partnership (Limited Partnership), clients of Kaiyuan Securities Co., Ltd., clients of China International Capital Corporation Wealth Securities Co., Ltd., and Shandong Yixing Venture Capital Co., Ltd. [1] - The cumulative holding ratio of institutional investors rose to 4.27% from the previous quarter [1]

长江证券承销保荐有限公司关于浙江海昇药业股份有限 公司 2025 年半年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《北京证券交易所股票上市规则》 等有关法律法规、规范性文件等的规定，长江证券承销保荐有限公司（以下简称 "保荐机构"）作为浙江海昇药业股份有限公司（以下简称"海昇药业""公司"） 的保荐机构，负责海昇药业的持续督导工作，并出具 2025 年半年度持续督导跟 踪报告。 一、持续督导工作概述 （一）审阅公司信息披露文件情况 保荐机构查阅公司募集资金使用台账、募集资金专户银行对账单，了解募投 项目实施进度并实地查看募投项目进展情况；获取公司购买理财产品的协议及相 关凭证，核查公司使用闲置募集资金进行现金管理是否符合法律规定；及时审阅 募集资金信息披露相关文件等。 （四）督导公司规范运作情况 对于公司重要信息披露文件，如定期报告、董事会决议、股东会决议、权益 分派等公告文件，保荐机构均履行了事前审阅程序。 （二）督导公司建立健全并有效执行规则制度情况 保荐机构已督导公司按照法律、法规、部门规章和相关业务规则及其他规范 性文件的要求健全并有效执行规则制度。报告期内，公司相关规章制度有效执行。 ...

证券代码：870656 证券简称：海昇药业 公告编号：2025-109 浙江海昇药业股份有限公司 2025 年半年度募集资金存放、管理与实际使用情况的 专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、募集资金基本情况 （一）实际募集资金净额、资金到位时间 根据中国证券监督管理委员会《关于同意浙江海昇药业股份有限公司向不 特定合格投资者公开发行股票注册的批复》（证监许可〔2024〕1 号），本公司 由主承销商长江证券承销保荐有限公司和联席主承销商甬兴证券有限公司采 用向战略投资者定向配售和网上向开通北京证券交易所交易权限的合格投资 者定价发行相结合的方式，向不特定合格投资者公开发行人民币普通股股票 2,000 万股，发行价为每股人民币 19.90 元，共计募集资金 39,800.00 万元， 扣除承销和保荐费用 3,085.00 万元后的募集资金为 36,715.00 万元，已由主 承销商长江证券承销保荐有限公司于 2024 年 1 月 26 日汇入本公司募集资金监 管账户。另减除上网发行费 ...

证券代码：870656 证券简称：海昇药业 公告编号：2025-110 1.会议召开时间：2025 年 8 月 21 日 2.会议召开地点：衢州市高新技术产业园区华阳路 36 号会议室 3.会议召开方式：现场方式 浙江海昇药业股份有限公司 4.发出董事会会议通知的时间和方式：2025 年 8 月 11 日以书面方式发出 第四届董事会第二次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 本议案已经公司第四届董事会审计委员会第二次会议审议通过。 会议应出席董事 5 人，出席和授权出席董事 5 人。 二、议案审议情况 （一）审议通过《关于公司 2025 年半年度报告及其摘要的议案》 1.议案内容： 5.会议主持人：董事长叶山海先生 具体内容详见公司于 2025 年 8 月 21 日在北京证券交易所信息披露网站 6.会议列席人员：公司副总经理、董事会秘书彭红江 （www.bse.cn）披露的《2025 年半年度报告》（公告编号：2025-107）、《20 ...

证券代码：870656 证券简称：海昇药业 公告编号：2025-106 浙江海昇药业股份有限公司 关于使用部分闲置募集资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权委托理财情况 （一）已授权委托理财基本信息 1．上年授权现金管理 浙江海昇药业股份有限公司（以下简称"公司"）于 2024 年 5 月 16 日召开 第三届董事会第十六次会议、第三届监事会第十五次会议，于 2024 年 6 月 3 日召开 2024 年第二次临时股东会议，审议通过了《关于使用部分闲置募集资金 进行现金管理的议案》，在确保资金安全、不影响募集资金投资项目建设的前提 下，公司拟使用额度不超过人民币 3 亿元（含本数）的闲置募集资金进行现金 管理，在上述额度范围内资金可以循环滚动使用，并授权公司董事长行使相关 投资决策权并签署相关文件，财务负责人负责具体组织实施及办理相关事宜。 具体内容详见公司在北京证券交易所信息披露平台（www.bse.cn）披露的《关 于使用部分闲置募集资金进行现金管理的 ...